In the wake of the Jared Loughner shooting in Arizona, we pointed out that the press seemed more interested in featuring Pharma-funded mouthpieces speculating on why Loughner wasn’t “treated” (drugged) and using this tragedy to start banging the drum for more government funding for more mental health treatment, (drugs) before even bothering to find out whether or not Loughner was, or had been, on psychiatric drugs. The logical question for anyone concerned with mental health would be; Was Loughner yet another in the long list of mass shooters already under the influence of psychiatric drugs documented to cause mania, psychosis, violence, homicidal and suicidal ideation that have resulted in 54 dead and 105 wounded in 10 such similar massacres? Isn’t that something we should know before spending billions more dollars on a pharmaceutically based mental health agenda? Shouldn’t we be investigating that instead of using this tragedy to get more funding for mental health “treatment”? So let’s just cut to the chase. The most prominent “mental health” groups using this shooting to cry out “give us billions more funding,” are themselves, funded by Pharma. Perhaps that answers the question of why despite the overwhelming evidence psychiatric drugs cause violence and even homicide, groups such as the National Alliance for Mental Illness (NAMI), which claims to be a “patient’s rights” organization for the “mentally ill”, are not calling for an investigation of what, if any role, psychiatric drugs played in this or any other mass shooting in the last 10 years, we are.
Senator Chuck Grassley has asked leading medical schools to describe their policies on ghostwriting as part of his continuing effort to shed light on financial ties between the pharmaceutical industry and medical professionals. “I’m interested in transparency, and academic institutions play an important role in establishing adequate and meaningful disclosure,” he said. Grassley also has conducted oversight and sought disclosure with physicians, continuing medical education and the patient advocacy community.